Pfizer has announced the launch of Rimegepant ODT, a new oral medication designed for migraine treatment in India. This innovative orally disintegrating tablet dissolves on the tongue, allowing for convenient administration without water. It provides rapid and sustained pain relief for up to 48 hours, making it a significant option for adults who have previously had insufficient responses to triptan medications. The introduction of Rimegepant is particularly important in India, where migraines affect approximately 213 million people annually, leading to an estimated productivity loss of 17.3 days per person each year. Pfizer aims to help individuals manage their migraine pain more effectively and regain lost productivity with this new treatment.